Stock listing

NASDAQ:QNCX Quince Therapeutics, Inc. Stock

Home listing (NASDAQ) of Quince Therapeutics, Inc.

Follow Quince Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:QNCX

$33.08 USD +0.25 (+0.8%)

Close on Oct 23, 2026

Past year -90.7% · daily closes, Oct 23, 2025 – Oct 23, 2026, adjusted for splits
Day range
$27.40 – $33.21 USDOct 23, 2026
Volume
89,800 sharesOct 23, 2026
Market cap
$33.64M USDAt the close on Oct 23, 2026 · price × 1.02M shares outstanding
52-week range
$15.10 – $910.00 USDLowest and highest trades, Oct 24, 2025 – Oct 23, 2026
Traded on an average day
$1.25M USDMedian day 26,282 shares · last 3 months, Jul 23, 2026 – Oct 23, 2026
Quince Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:QNCX · Home$33.08 USD+0.25 (+0.8%)89,800$31.61$33.21$27.40$32.83Close on Oct 23, 2026

Daily closes

Last 3 months, Jul 23, 2026 – Oct 23, 2026 · NASDAQ:QNCX · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$33.08+0.25+0.8%$31.61$33.21$27.4089,800
$32.83-1.85-5.3%$35.70$35.70$31.34166,100
$34.68-5.59-13.9%$39.54$40.98$34.00216,300
$40.27+5.82+16.9%$34.99$41.00$34.79317,100
$34.45+2.42+7.6%$31.17$34.61$31.0141,600
$32.03-1.20-3.6%$31.18$34.93$31.1811,600
$33.23+3.23+10.8%$28.99$33.71$28.999,000
$30.00+2.13+7.6%$26.72$30.23$26.7226,900
$27.87-4.53-14.0%$28.51$30.80$25.1384,300
$32.40+0.67+2.1%$29.51$32.61$26.5076,900
$31.73+2.37+8.1%$30.50$37.00$29.84138,700
$29.36+2.64+9.9%$27.10$29.80$26.6531,900
$26.72-0.09-0.3%$26.74$27.95$26.7212,703
$26.81-1.29-4.6%$27.68$28.15$26.8127,826
$28.10-1.10-3.8%$29.00$29.78$28.0022,095
$29.20-1.48-4.8%$30.20$31.06$29.2068,380
$30.68-0.33-1.1%$31.99$31.99$29.2020,920
$31.01-0.16-0.5%$31.97$32.59$30.6210,678
$31.17+2.17+7.5%$28.70$32.00$26.4521,795
$29.00-2.00-6.5%$30.00$31.20$26.9040,796
$31.00+1.00+3.3%$30.40$31.00$29.9810,336
$30.00-0.15-0.5%$30.81$30.81$29.6010,861
$30.15-1.20-3.8%$31.01$31.01$29.037,589
$31.35+0.35+1.1%$32.79$32.99$30.5024,000
$31.00+1.52+5.2%$29.46$31.00$28.5413,675
$29.48+2.47+9.1%$27.20$30.00$27.2048,836
$27.01-0.16-0.6%$27.17$27.83$26.6211,883
$27.17-1.675-5.8%$27.39$28.50$25.7849,302
$28.85+0.255+0.9%$28.57$29.99$27.1515,930
$28.59-0.96-3.2%$29.28$29.28$27.0033,567
$29.55+0.59+2.0%$28.88$30.44$28.8811,341
$28.96-1.355-4.5%$30.00$30.00$28.313,634
$30.32+0.815+2.8%$29.47$31.03$28.7610,329
$29.50-1.82-5.8%$31.88$31.88$29.0112,708
$31.32+0.77+2.5%$30.53$33.40$30.0037,864
$30.55-1.60-5.0%$32.96$32.96$30.2310,987
$32.15+0.04+0.1%$32.92$33.05$31.9615,484
$32.11-0.46-1.4%$33.03$33.48$32.1116,489
$32.57-1.18-3.5%$34.04$34.04$31.4734,168
$33.75+1.25+3.8%$32.91$35.34$31.8527,170
$32.50+1.19+3.8%$31.99$32.86$29.9516,517
$31.31+0.38+1.2%$31.90$32.01$31.3113,714
$30.93-2.55-7.6%$32.40$33.69$30.9317,450
$33.48-0.45-1.3%$33.00$33.51$32.505,729
$33.93+1.82+5.7%$32.77$34.09$32.579,537
$32.11-2.46-7.1%$34.57$35.15$31.6223,333
$34.57+1.66+5.0%$32.89$35.23$31.2523,403
$32.91-1.21-3.5%$33.00$34.86$32.2728,623
$34.12+0.08+0.2%$34.95$35.41$33.0838,991
$34.04+1.63+5.0%$31.78$35.20$31.7826,183
$32.41+1.15+3.7%$30.89$33.74$30.8934,484
$31.26-1.47-4.5%$32.92$33.26$30.0444,134
$32.73+2.08+6.8%$31.50$33.11$30.5035,224
$30.65+0.45+1.5%$30.00$31.47$29.6833,702
$30.20+0.66+2.2%$29.92$30.77$29.2530,356
$29.54+0.66+2.3%$29.17$30.32$28.5526,120
$28.88+1.47+5.4%$27.16$29.99$27.1642,790
$27.41+2.445+9.8%$25.36$27.48$24.8126,381
$24.97+1.575+6.7%$23.51$26.62$23.5054,412
$23.39+0.36+1.6%$23.47$24.59$21.5535,298
$23.03+1.03+4.7%$21.81$23.66$21.7658,793
$22.00+2.63+13.6%$19.51$22.41$18.4380,498
$19.37+1.52+8.5%$17.47$19.37$17.3637,630
$17.85-0.0050.0%$17.72$18.49$17.6018,093
$17.86-0.425-2.3%$18.40$18.40$17.5115,247
$18.28-0.26-1.4%$18.24$18.64$17.8021,631

Splits

2 splits since 2026 · NASDAQ:QNCX · every price before a split is adjusted for it

DayRatioWhat
1-for-20Consolidation
1-for-10Consolidation
Ticker
NASDAQ:QNCX
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Quince Therapeutics, Inc. news

Quince Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
13 in the last 12 months · 51 in all · newest Oct 9, 2026 · oldest 2023
Decks
4 decks · latest November 2026

Where Quince Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:QNCX · Home listing · This pageNASDAQUnited StatesUSD
BOATS:QNCXBOATSUnited StatesUSD

Valuation

Price/book 0.3× against a median of 1.2×: the lowest of 11 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Oct 23, 2026

Enterprise value
−$82.34M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
0.3×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
1.84

Biotechnology: the 10 companies nearest in size, of 891 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Quince Therapeutics, Inc. · NASDAQ:QNCXUS$33.64M−US$82.34Mn/an/an/a0.3×n/a0.0×1.84
Cantargia AB · OMXSTO:CANTAUS$35.54MUS$13.84M2.2×0.5×0.9×1.4×52.8%0.0×n/a
Cue Biopharma, Inc. · NASDAQ:CUEUS$34.69M−US$23.25Mn/a−0.7×n/a0.9×−580.0%0.0×2.35
B&K Corporation Limited Class H · HKEX:2396US$33.16M−US$47.27Mn/a−603×n/a0.4×n/a0.0×n/a
Veru Inc. · NASDAQ:VERUUS$33.08MUS$9.20Mn/an/an/a1.2×n/a0.0×1.92
Actinium Pharmaceuticals, Inc. (Delaware) · AMEX:ATNMUS$33.01MUS$5.49M3.1×n/a0.6×1.3×n/a0.1×0.71
Neurizon Therapeutics Limited · ASX:NUZUS$32.85MUS$26.61Mn/a2.3×n/a3.9×−61.0%0.3×n/a
Transcenta Holding Limited · HKEX:6628US$32.41MUS$52.57Mn/a12.4×n/a0.4×−569.5%0.3×n/a
CJ Bioscience. Inc. · KRX:311690US$32.33MUS$1.90Mn/a0.7×n/a1.0×−607.2%0.0×n/a
Enimmune Corporation · TPEX:6564US$31.75MUS$26.88Mn/a18.4×n/a10.4×−341.0%0.3×n/a
Molecure SA · GPW:MOCUS$31.63MUS$29.58Mn/an/an/a1.3×n/a0.0×n/a
Median of the othersUS$32.93MUS$11.52M2.6×0.7×0.7×1.2×−455.3%0.0×1.92

Forecasts

Analysts' consensus from EODHD, read Nov 13, 2026. Not 6ix's view and not investment advice.

Price target
75.00 USD · Analysts' mean
EPS, year to Dec 2026
-3.65 · 3 analysts

Team and board

Officers

OfficerRole
Brigette RobertsChief Executive Officer & Board Member

Board

DirectorRole
Brigette RobertsChief Executive Officer & Board Member
Catherine BonuccelliBoard Member
Drayton WiseBoard Member
James E. ValentineBoard Member
Leone PattersonBoard Member

Events

QuarterResultsShare move
Quarter to Sep 30, 2026Nov 11, 2026
Q2 2026Aug 14, 2026 · Before open+5.0%
Q1 2026Apr 10, 2026 · After close
Q4 2025Mar 3, 2026+5.0%
Q3 2025Nov 12, 2025 · After close−1.8%
Q2 2025Aug 11, 2025 · After close+14.4%
Q1 2025May 12, 2025 · Before open+1.0%
Q4 2024Mar 24, 2025 · After close−2.1%
Q3 2024Nov 13, 2024 · After close+19.5%
Q2 2024Aug 13, 2024 · After close−4.5%
All 20 quarters
QuarterResultsShare move
Q1 2024Apr 1, 2024 · After close−3.7%
Q4 2023Feb 14, 2024 · Before open+7.6%
Q3 2023Nov 14, 2023 · After close−0.8%
Q2 2023Aug 3, 2023 · After close−1.6%
Q1 2023May 15, 2023 · After close+1.3%
Q4 2022Mar 15, 2023 · After close−1.3%
Q3 2022Nov 9, 2022 · After close+3.9%
Q2 2022Aug 9, 2022 · After close+7.9%
Q1 2022May 10, 2022 · After close−15.6%
Q4 2021Mar 1, 2022 · After close+4.1%

Open Events

Decks

DeckKindSlidesDate
IRulya Therapeutics — Investor Presentation (November 2026)Investor deck35 slidesNovember 2026
Investor Presentation (May 2026)Investor deck32 slidesMay 18, 2026
Technical Presentation (May 2026)Technical16 slidesMay 2026
Merger or Acquisition (July 2023)Merger or acquisition19 slidesJul 24, 2023

Open Decks

Financings

RaiseDate
Private placement of series C non-voting convertible preferred stock and warrants
Closed: US$115M raised · warrants that could bring up to an additional $83 million upon exercise (including…
Aug 14, 2026
Private placement of shares of common stock (or pre-funded warrants) and accompanying common warrants
Closed: US$11.5M raised · US$1.325 a share · Warrants at US$1.2 for 60 months · Citizens Capital Markets +2
Dealers: Citizens Capital Markets (lead), Maxim Group LLC, Brookline Capital Markets
Buyers: Nantahala Capital (led the private placement); ADAR1 Capital Management; Quince senior management
Insiders: Members of Quince's senior management participated
Use of proceeds: Working capital and general corporate purposes, including Phase 3 NEAT trial enrollment in A-T, R&D, G&A and capital expenditures
Jun 18, 2025

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue00000000
Cost of revenue142.0K186.0K322.0K175.0K344.0K332.0K188.0K51.0K45.0K
Gross profit-142.0K-186.0K-322.0K-175.0K-344.0K-332.0K-188.0K-51.0K-45.0K
Research and development35.4M18.6M9.45M25.2M60.8M61.3M30.2M10.1M9.10M
Selling, general and administrative15.0M17.6M17.7M26.0M29.5M17.6M8.95M2.03M1.27M
Operating income-50.4M-57.3M-34.6M-52.0M-90.3M-78.9M-39.2M-12.1M-10.4M
Depreciation and amortization142.0K186.0K322.0K204.0K344.0K332.0K188.0K51.0K45.0K
EBITDA-50.3M-57.1M-34.3M-51.8M-90.0M-78.6M-39.0M-12.1M-10.3M
Interest expense568.0K373.0K2.04M2.19M957.0K1.64M
Income before tax-80.8M-56.7M-31.6M-51.9M-89.9M-76.8M-37.0M-12.5M-12.2M
Income tax3.21M87.0K-197.0K-284.0K-620.0K2.17M-188.0K357.0K1.86M
Net income-84.0M-56.8M-31.4M-51.7M-89.9M-76.8M-37.0M-12.5M-12.2M
Earnings per share, basic-335.27-262.71-168.57-308.45-605.31-526.79-388.61-115.78-113.54

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents5.81M6.21M20.8M44.6M69.7M66.8M51.2M24.9M7.34M
Short-term investments11.9M34.6M54.3M45.6M37.1M67.0M48.6M46.8M
Receivables3.62M882.0K993.0K1.00M1.13M
Inventory2.29M2.25M
Current assets22.9M44.0M77.4M93.7M111.7M137.9M106.1M72.6M7.54M
Property, plant and equipment393.0K1.43M1.10M1.33M283.0K
Goodwill017.6M0
Total assets93.5M114.5M180.2M103.9M133.2M189.5M124.4M72.9M7.72M
Accounts payable2.22M2.90M2.03M570.0K4.91M3.56M3.08M495.0K517.0K
Current liabilities43.2M7.28M9.57M3.07M14.2M17.0M8.89M1.46M1.76M
Long-term debt14.3M13.4M
Total debt18.5M14.8M13.8M453.0K1.16M446.0K7.17M
Total liabilities129.2M84.3M95.1M3.32M14.6M17.2M8.89M1.46M28.0M
Shareholders' equity-35.7M30.1M85.1M100.6M118.6M172.3M115.5M71.4M-20.3M
Shares outstanding250.5K216.3K186.2K167.5K148.6K145.9K95.2K107.8K107.8K

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations-41.4M-31.9M-18.3M-44.0M-62.9M-50.8M-33.3M-11.7M-9.83M
Capital spending-352.0K-257.0K-160.0K-133.0K-180.0K-52.0K-55.0K-212.0K-77.0K
Free cash flow-41.8M-32.2M-18.5M-44.2M-63.1M-50.9M-33.3M-11.9M-9.90M
Cash from investing23.2M21.9M-5.76M18.0M59.0M-52.4M-17.7M-46.8M-77.0K
Cash from financing17.9M-4.78M143.0K707.0K6.81M118.9M77.4M75.9M7.75M
Share buybacks63.7M16.5M
Change in cash-403.0K-14.5M-23.8M-25.1M2.88M15.6M26.3M17.5M-2.15M

Open Financials

Cap table

Built by 6ix from Quince Therapeutics, Inc.’s releases · as of Aug 14, 2026

Common shares
1,017,063
Fully diluted
1,017,063

Fully diluted

LineShares
Common shares1,017,063

Warrants and options

Lot
Warrants · expiry not stated
Warrants · US$1.20 · expire about Jun 2030

Share count over time

CountShares
Nov 22, 20261,017,063

Open Cap table

Shareholders

Funds

HolderSharesOf the companyValueChangeAs of
Fidelity Extended Market Index Fund26,5882.6%US$30,576NewMay 31, 2026
Fidelity Total Market Index Fund8,5370.84%US$9,818NewMay 31, 2026
Fidelity Series Total Market Index Fund6,9430.68%US$7,984NewMay 31, 2026
Fidelity Nasdaq Composite Index Fund2,5340.25%US$2,914NewMay 31, 2026

Big stakes

HolderStakeSharesDate
Integrated Core Strategies (US) LLC7.20%1.4MJun 4, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Karen Smith
Other companies: Context Therapeutics Inc. (Independent Director · Since at least Sep 4, 2024); Skye Bioscience, Inc. (Director · Since at least Jul 2, 2024); Sangamo Therapeutics, Inc. (Director · Since at least Jun 26, 2018); Aurinia Pharmaceuticals Inc (Director · Aug 18, 2023 – Nov 21, 2024 · Past); Tourmaline Bio Inc. (Director · May 16, 2022 – Jun 13, 2023 · Past); Emergent BioSolutions Inc. (EVP, Chief Medical Officer · May 21, 2020 – May 7, 2021 · Past); Antares Pharma Inc (Director · Mar 1, 2019 – May 24, 2022 · Past); Acceleron Pharma Inc (Director · Nov 15, 2017 – Nov 19, 2021 · Past); Sucampo Pharmaceuticals Inc (Director · Jul 15, 2017 – Feb 13, 2018 · Past); Jazz Pharmaceuticals plc (EVP, R&D and CMO · Apr 13, 2015 – Mar 5, 2018 · Past)
Chief Medical Officer · May 19, 2022 – Feb 1, 2023 · Past
Rajiv Patni
Other companies: Septerna, Inc. (Chief Medical Officer · Since at least Aug 24, 2026); BioXcel Therapeutics, Inc. (Director · Since at least Jan 15, 2025); Reata Pharmaceuticals Inc (EVP, Chief R&D Officer · Jun 12, 2023 – Sep 26, 2023 · Past); Portola Pharmaceuticals Inc (EVP, CMO · Feb 3, 2020 – Jul 2, 2020 · Past); Adamas Pharmaceuticals Inc (Chief Medical Officer · Jun 8, 2015 – Apr 8, 2019 · Past); Ocera Therapeutics Inc (Chief Development Officer · Sep 2, 2014 – May 7, 2015 · Past)
Director · Since at least Feb 15, 2024
Charles Ryan
Other companies: Polaryx Therapeutics, Inc. (Director · Since at least Jan 29, 2026); Neurotrope Inc (Director · Dec 14, 2017 – Dec 1, 2020 · Past); BioRestorative Therapies, Inc. (Director · Apr 6, 2015 – Mar 25, 2019 · Past); BNB Plus Corp. (Director · Nov 14, 2014 – May 17, 2019 · Past)
President · Since at least Sep 1, 2023
Christopher P Lowe
Other companies: Vincerx Pharma Inc (Director · May 13, 2021 – Aug 24, 2022 · Past); Anthera Pharmaceuticals Inc (CFO and Chief Business Officer · Feb 23, 2010 – May 17, 2013 · Past); Hansen Medical Inc (Interim CFO, Director · Nov 15, 2006 – Jul 27, 2016 · Past)
Interim CEO, COO & CFO · May 8, 2019 – Mar 3, 2022 · Past
Una S. Ryan
Other companies: RenovoRx, Inc. (Director · Since at least Aug 25, 2021); Albany Molecular Research Inc (Director · Oct 30, 2006 – May 10, 2017 · Past); Celldex Therapeutics, Inc. (President & CEO, Director · Jan 3, 2006 – Mar 7, 2008 · Past)
Director · Since at least May 8, 2019
Caryn Gordon McDowell
Other companies: Revance Therapeutics, Inc. (SVP, GC & Secretary · May 1, 2018 – Feb 15, 2020 · Past); Cytokinetics, Incorporated (GC & Chief Compliance Officer · May 18, 2016 – Feb 27, 2018 · Past)
Chief Legal & Adm. Officer · May 5, 2020 – Jun 6, 2022 · Past
David Lamond
Other companies: Lucira Health Inc (Director · Feb 4, 2021 – Jun 1, 2022 · Past); Applied Molecular Transport Inc (Director · Jun 4, 2020 – May 24, 2022 · Past)
Director · Since at least May 8, 2019
Brigette Roberts
Other companies: Ligand Pharmaceuticals Incorporated (Director · Jan 4, 2006 – Jan 3, 2007 · Past)
Chief Executive Officer & Board Member · Since at least May 18, 2026
Casey Lynch
Other companies: Longboard Pharmaceuticals Inc (Director · Mar 11, 2021 – Dec 2, 2024 · Past)
Chief Executive Officer, Director · May 8, 2019 – Jan 3, 2022 · Past
Christopher J. Senner
Other companies: Exelixis, Inc. (Executive Vice President and Chief Financial Officer · Since at least Jul 15, 2015)
Director · Since at least May 8, 2019
All 28 people
PersonSeat
Dirk Thye
Other companies: Cidara Therapeutics Inc (Chief Medical Officer · Apr 14, 2015 – Mar 16, 2016 · Past)
CEO and CMO, Director · Since at least May 19, 2022
June Bray
Other companies: BioXcel Therapeutics, Inc. (Director · Since at least Mar 1, 2021)
Director · Since at least Jun 9, 2022
Kevin Young
Other companies: Gilead Sciences, Inc. (Chief Operating Officer · May 24, 2016 – Feb 15, 2018 · Past)
Director · May 8, 2019 – Jun 8, 2020 · Past
Luca Benatti
Other companies: Intercept Pharmaceuticals Inc (Director · Jul 17, 2014 – Nov 8, 2023 · Past)
Director · Since at least Oct 23, 2023
Marwan Sabbagh
Other companies: CervoMed Inc. (Director · Since at least Aug 16, 2023)
Director · Mar 14, 2022 – Mar 14, 2022 · Past
Philip S Low
Other companies: Endocyte Inc (Chief Science Officer, Director · Feb 4, 2011 – Dec 21, 2018 · Past)
Director · May 19, 2022 – May 19, 2022 · Past
Brendan HannahCBO, COO & CCO · Since at least May 19, 2022
Catherine BonuccelliBoard Member · Since at least Oct 9, 2026
Drayton WiseBoard Member · Since at least Oct 9, 2026
Guenter JanhoferChief Scientific Officer · Oct 23, 2023 – Oct 23, 2023 · Past
James ValentineBoard Member · Since at least Oct 9, 2026
Kristen GafricSVP, Legal & Administration · May 8, 2019 – Feb 6, 2020 · Past
Leone PattersonBoard Member · Since at least Oct 9, 2026
Leslie HolsingerEVP, Preclinical Development · May 8, 2019 – Jun 6, 2022 · Past
Margaret McLoughlinDirector · Since at least May 8, 2019
Michael J DetkeChief Medical Officer · May 8, 2019 – Mar 3, 2022 · Past
Stephen S DominyChief Scientific Officer, Director · May 8, 2019 – Jan 3, 2022 · Past
Ted MonohonChief Accounting Officer & VP · Feb 9, 2021 – Mar 6, 2023 · Past

Open People

Log in to ask 6ix AI your own questions about Quince Therapeutics, Inc.